市場調查報告書

多發性骨髓瘤:市場分析,流行病學,到2030年的預測

Multiple Myeloma - Market Insights, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 955303
出版日期 內容資訊 英文 403 Pages
商品交期: 最快1-2個工作天內
價格
多發性骨髓瘤:市場分析,流行病學,到2030年的預測 Multiple Myeloma - Market Insights, Epidemiology and Market Forecast - 2030
出版日期: 2020年08月01日內容資訊: 英文 403 Pages
簡介

多發性骨髓瘤(MM)是漿細胞癌,是漿細胞癌變並失控的狀態。癌性漿細胞會產生異常蛋白(抗體),例如單克隆免疫球蛋白,單克隆蛋白(M蛋白),M尖峰和副蛋白。正常漿細胞存在於骨髓中,是免疫系統的重要組成部分。多發性骨髓瘤是美國第二大最常見的血液癌,僅次於非霍奇金淋巴瘤,男性患者多於女性。骨髓瘤的發生與年齡密切相關,並且隨著年齡的增長而增加,最常被診斷為65至74歲。大約95%的病例被診斷為處於遠處或轉移階段,其5年相對生存率約為53%。多發性骨髓瘤的確切病因尚不清楚,但DNA的某些變化已顯示會使漿細胞癌變。通常以減輕或減輕其症狀並減少骨髓中的骨髓瘤細胞數量為目的來治療患者。

本報告按疾病概述,診斷,流行病學和患者人數(按國家/地區)概述了直至2030年美國,德國,法國,意大利,西班牙,英國,日本和中國的MM流行病。它提供有關流行病,當前治療,未解決的需求,現場治療和新治療的信息。

目錄

第1章主要調查結果

第2章執行摘要

第3章主要專家的觀點

第4章SWOT分析

第5章市場概述

第6章疾病背景和概述

  • 簡介
  • 多發性骨髓瘤的特徵
    • 血細胞計數低
    • 骨骼和鈣質問題
    • 傳染病
    • 腎臟問題
  • 多發性骨髓瘤的原因
  • 多發性骨髓瘤的危險因素
  • 體徵和症狀
    • 骨頭問題
    • 血鈣濃度升高
    • 神經系統症狀
    • 腎臟問題
  • 多發性骨髓瘤的病因
    • 發生進展的分子機制
    • 多發性骨髓瘤及其癌前體的分子病因學
  • 多發性骨髓瘤的病理生理學
  • 與患者相關的危險因素
  • 多發性骨髓瘤的生物標誌物
    • 血清M蛋白和輕鏈作為生物標誌物
    • 潛在的蛋白質組學生物標誌物
    • 多發性骨髓瘤的細胞生物學標誌物

第7章多發性骨髓瘤的診斷

  • 檢驗
  • 活檢
  • 圖像檢查
  • 多發性骨髓瘤的分期

第8章流行病學和患者人群

  • 流行病學的主要發現
  • 假設和依據:8個主要國家
  • 流行病學情況:8個主要國家
    • 總事件案例
    • 有症狀的病例總數
    • 性別案例
    • 按年齡劃分的案件
    • 按治療線分類的病例

第9章美國流行病學

  • 總事件案例
  • 有症狀的病例總數
  • 性別案例
  • 按年齡劃分的案件
  • 按治療線分類的病例

第10章歐洲5國流行病學

  • 德國
    • 總事件案例
    • 有症狀的病例總數
    • 性別案例
    • 按年齡劃分的案件
    • 按治療線分類的病例
  • 法國
  • 意大利
  • 西班牙
  • 英國

第11章日本流行病學

  • 總事件案例
  • 有症狀的病例總數
  • 性別案例
  • 按年齡劃分的案件
  • 按治療線分類的病例

第12章中國流行病學

  • 總事件案例
  • 有症狀的病例總數
  • 性別案例
  • 按年齡劃分的案件
  • 按治療線分類的病例

第13章治療

  • 多發性骨髓瘤的藥物治療
    • 化學療法
    • 皮質類固醇(類固醇)
    • 免疫調節劑
    • 蛋白□體抑製劑
    • Histon脫乙□基□(HDAC)抑製劑
    • 單克隆抗體
    • 核出口抑製劑
    • 藥物組合
    • 雙膦酸鹽
  • 放射治療
  • 手術
  • 幹細胞移植
    • 自體移植
    • 同種異體移植
  • 支持療法
    • 靜脈免疫球蛋白(IVIG)
    • 低血細胞計數的治療
    • 等離子交換
  • 分階段治療方案
    • 孤立性漿細胞瘤
    • 多發性骨髓瘤的悶燒
    • 活動性(症狀性)骨髓瘤
  • 復發情況下影響治療選擇的因素
  • 多發性骨髓瘤治療指南

第14章不受支持的需求

第15章患者旅程

第16章臨床試驗的關鍵終點

第17章已啟動的治療方法

  • Sarclisa (Isatuximab): Sanofi
  • Xpovio(Selinexor):Karyopharm
  • Darzalex(Daratumumab):Janssen Biotech
  • Empliciti(Elotuzumab):Bristol Myers Squibb/AbbVie
  • Velcade (Bortezomib): Takeda Pharmaceutical/Janssen Pharmaceutical
  • Pomalyst/Imnovid:Bristol-Myers Squibb Company(Celgene)
  • Revlimid (Lenalidomide): Celgene
  • Farydak(Panobinostat):Secura Bio
  • Kyprolis (Carfilzomib): Amgen (Onyx therapeutics)
  • Ninlaro (Ixazomib): Takeda Pharmaceutical (Millennium Pharmaceuticals)

第18章新療法

  • Belantamab Mafodotin (GSK2857916): GlaxoSmithKline
  • Idecabtagene vicleucel(bb2121/ide-cel): Bristol-Myers Squibb/Bluebird bio
  • Venetoclax(ABT-199):AbbVie and Roche
  • JNJ-68284528(LCAR-B38M/JNJ-4528):Janssen Biotech/Nanjing Legend Biotech
  • Melflufen (melphalan flufenamide): Oncopeptides AB
  • Keytruda(Pembrolizumab):Merck Sharp&Dohme Corp.
  • Cetrelimab(JNJ-63723283):Janssen Research & Development
  • REGN5458:Regeneron Pharmaceuticals
  • Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
  • Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy: RAPA Therapeutics
  • Encorafenib與Binimetinib併用:Pfizer(Array Biopharma)
  • CLR 131(131-CLR1404):Cellectar Biosciences
  • NY-ESO-1C259T細胞:Adaptimmune Therapeutics/GlaxoSmithKline/Merck Sharp&Dohme Corp
  • BL-8040:BioLineRx
  • GVAX (GM-CSF) Vaccine:Celgene/Aduro Biotech
  • ECT-001:ExCellThera
  • TAK-079:Takeda
  • GBR 1342(ISB 1342):Glenmark (Ichnos Sciences SA)
  • P-BCMA-101 CAR-T細胞:Poseida Therapeutics
  • Opdivo (Nivolumab): Bristol-Myers Squibb
  • AMG 420(BI 836909):Amgen
  • PBCAR269A:Precision BioSciences
  • JCARH125(Orvacabtagene autoleucel; Orva-cel):Juno Therapeutics(Bristol-Myers Squibb子會社)
  • MP0250:Molecular Partners AG
  • Teclistamab(JNJ-7957; JNJ-64007957):Janssen Pharmaceutical
  • Descartes-11: Cartesian Therapeutics
  • Imfinzi (Durvalumab): AstraZeneca
  • Imbruvica(Ibrutinib):Abbvie(Pharmacyclics)、Johnson&Johnson
  • Felzartamab(MOR202):MorphoSys AG/I-Mab Biopharma
  • Chidamide (Epidaza):Chipscreen Biosciences

第19章主要市場分析

  • 主要發現
  • 市場前景
  • 中國市場前景

第20章市場規模

  • 市場總規模
  • 按治療方法劃分的總市場規模

第21章美國市場規模

第22章:5個歐洲國家的市場規模

  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 英國

第23章日本市場規模

第24章中國市場規模

第25章市場准入和贖回

  • 難治性多發性骨髓瘤復發的三聯療法進入歐洲市場的挑戰

第26章市場增長因素

第27章市場壁壘

第28章附錄

第29章Delve Insight服務內容

第30章免責聲明

第31章關於Delve Insight

目錄
Product Code: DIMI0318

DelveInsight's 'Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China.

The MM market report provides current treatment practices, emerging drugs, MM market share of the individual therapies, current and forecasted MM market size from 2017 to 2030 segmented by seven major markets. The Report also covers current MM treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
  • China

Study Period: 2017-2030

Multiple Myeloma (MM): Disease Understanding and Treatment Algorithm

Multiple Myeloma Overview

According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65-74. Approximately 95% of cases are diagnosed at a distant stage or metastatic stage and 5-year relative survival rate for this stage is around 53%. Most of the researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. DNA is the chemical that transfers the instructions for nearly everything the cells do in the body. Patients with active myeloma generally receive treatment aimed at reducing or at least providing relief from symptoms and reducing the number of myeloma cells in the bone marrow.

Multiple Myeloma Diagnosis

Multiple myeloma is often diagnosed based on tests, the patient's symptoms and the doctor's physical exam of the patient. A diagnosis of multiple myeloma requires either:

1. A plasma cell tumor (proven by biopsy) or at least 10% plasma cells in the bone marrow

2. At least one of the following:

  • High blood calcium level
  • Poor kidney function
  • Low red blood cell counts (anemia)
  • Holes in the bones from tumor found on imaging studies (CT, MRI, PET scan)
  • Increase in one type of light chain in the blood so that one type is 100 times more common than the other
  • 60% or more plasma cells in the bone marrow

Multiple Myeloma Treatment

The main treatment options include stem cell transplant, chemotherapy, targeted therapy, corticosteroids, proteasome inhibitors, immunomodulators, monoclonal antibodies, surgery, and radiation therapy. Also, the survival of patients with myeloma has also improved due to the development and approval of new treatments. MM treatment strategies have also evolved with the emergence of new therapies with a novel mechanism of action and also with more complex combination regimens being used, such as quadruplets, triplets, and doublets.

Multiple Myeloma (MM) Epidemiology

The MM epidemiology division provide the insights about historical and current MM patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The MM epidemiology division provides insights about historical and current patient pool and forecasted trends for each seven major countries. The MM epidemiology data are studied through MM possible division to give a better understanding of the Disease scenario in the 8MM.

The disease epidemiology covered in the report provides historical as well as forecasted MM epidemiology [segmented as Total Incidence of Multiple Myeloma, Total Symptomatic Cases of MM, Total Incident Cases of MM Segmented by Gender, Total Incident Cases of MM Segmented by Age, Total Cases of MM by Line of Treatment] scenario of MM in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2017 to 2030

Country Wise- Multiple Myeloma Epidemiology

  • In the year 2017, the total incident case of Multiple Myeloma was 85,971 cases in the 8MM. The United States, in 2017, accounted for 30,271 cases (the highest number), which will probably rise by the year 2030.
  • Among the EU-5 countries, the highest number of incident cases of Multiple Myeloma was in Germany 7,337, in the year 2017. In the year 2017, the total incident cases of Multiple Myeloma were 7,504 in Japan.
  • In the year 2017, the total incident cases of Multiple Myeloma was 19,536 in China, which might increase cases by 2030.

Multiple Myeloma Drug Chapters

Drug chapter segment of the Multiple Myeloma report encloses the detailed analysis of Multiple Myeloma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Multiple Myeloma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Multiple Myeloma Marketed Drugs

Sarclisa (Isatuximab): Sanofi

Sarclisa- a product of Sanofi is a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells. It is basically manufactured and designed to initiate programmed tumor cell death (apoptosis) and immunomodulatory activity.

Xpovio (Selinexor): Karyopharm

Karyopharm' potential candidate Selinexor is an oral, first-in-class, selective inhibitor of nuclear export also known as SINE, compound., till date it has only been approved by the USFDA, in fact has been given accelerated approval on the response rate for one specific indication. It has only been approved by the US FDA in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Darzalex (Daratumumab): Janssen Biotech

Darzalex (daratumumab) is a prescription medicine used to treat a type of blood cancer called multiple myeloma. Darzalex is not chemotherapy. It is a human IgG1k monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. In November 2015, Darzalex first received the US FDA approval as a monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to a PI and an immunomodulatory agent. Recently, in April 2020, the US FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab. Darzalex Faspro is approved in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients.

Products detail in the report…

Multiple Myeloma Emerging Drugs

Belantamab Mafodotin (GSK2857916): GlaxoSmithKline

GlaxoSmithKline's lead candidate, Belantamab Mafodotin (GSK2857916) is a first-in-class, anti-BCMA immunoconjugate with an afucosylated, humanized IgG1 anti-BCMA monoclonal antibody conjugated by a protease-resistant maleimidocaproyl linker to a microtubule-disrupting agent, monomethyl auristatin F (MMAF). The drug linker technology is licensed from Seattle Genetics; monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa. This candidate has received orphan drug designation from the EMA and the US FDA for multiple myeloma. Apart from this, the EMA and the US FDA have also granted PRIME designation and Breakthrough Therapy designation, respectively

Idecabtagene vicleucel (bb2121/ ide-cel): Bristol-Myers Squibb/Bluebird bio

Idecabtagene vicleucel (ide-cel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapy co-developed, and co-promoted by Bristol Myers Squibb and Bluebird bio for the treatment of adult patients with multiple myeloma who have received at least three prior therapies. The ide-cel CAR is comprised of a murine extracellular single-chain variable fragment (scFv) specific for recognizing BCMA, attached to a human CD8 α hinge and transmembrane domain fused to the T cell cytoplasmic signaling domains of CD137 4-1BB and CD3-chain, in tandem

Venetoclax (ABT-199): AbbVie and Roche

Venetoclax (Venclexta, Venclyxto) is an oral B-cell lymphoma-2 (BCL-2) inhibitor developed by AbbVie and Genentech. It is used for the treatment of adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) and in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing proapoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization, and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2. In March 2019, the US FDA placed a partial clinical hold on Venetoclax's multiple myeloma trials after new safety concerns were raised during a review of the BELLINI Phase III trial (NCT02755597). In July 2019, the US FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol (Myeloma Positive for the t(11;14) Genetic Abnormality), including new risk mitigation measures, protocol-specified guidelines and updated futility criteria (AbbVie News Center, 2019).

JNJ-68284528 (LCAR-B38M/JNJ-4528): Janssen Biotech/Nanjing Legend Biotech

JNJ-68284528 (LCAR-B38M/JNJ-4528) is currently being investigated for the treatment of patients with multiple myeloma who have received at least three prior regimens, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody, and have documented disease progression within 12 months of starting the most recent therapy, or are double refractory to an immunomodulatory drug and proteasome inhibitor. This product is being evaluated under licensing and collaboration agreement between Janssen and Legend Biotech.

Melflufen (melphalan flufenamide): Oncopeptides AB

Melflufen is a first-in-class anti-cancer peptide-drug conjugate that rapidly produces an alkylating payload into tumor cells. The phase III clinical study (OCEAN, OP-103) is currently enrolling and has been approved under the US FDA's Special Protocol Assessment. In the OCEAN study, melflufen is compared directly against the current standard of care in patients with relapsed or refractory multiple myeloma.

REGN5458: Regeneron Pharmaceuticals

REGN5458 is a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells. In December 2019, the company presented the results at the American Society of Hematology (ASH) Annual Meeting.

JCARH125 (Orvacabtagene autoleucel; Orva-cel): Juno Therapeutics (a Bristol-Myers Squibb company)

JCARH125 is a BCMA-targeting CAR T cell product candidate that is being developed by Juno Therapeutics. It incorporates several important elements that are believed to be important for maximizing patient benefit, including a next-generation manufacturing process, a fully-human binding domain, and a 4-1BB costimulatory domain. JCARH125 has received orphan drug designation from the FDA for multiple myeloma.

Products detail in the report…

Multiple Myeloma Market Outlook

Key Findings

According to DelveInsight, Multiple Myeloma market in the 8MM is expected to change in the study period 2017-2030. The therapeutic market of Multiple Myeloma in seven major markets was found to be USD 14,111 million in 2017 which is expected to increase during study period (2017-2030).

The United States Market Outlook

In 2017, the total market size of MM therapies was found to be USD 9,467 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of MM therapies was found to be USD 3,139 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of MM therapies in Japan was found to be USD 1,019 million in 2017.

China Japan Market Outlook

The total market size of MM therapies in Japan was found to be USD 487million in 2017.

Multiple Myeloma Pipeline Development Activities

The drugs which are in pipeline includes:

1. Belantamab Mafodotin (GSK2857916): GlaxoSmithKline

2. Idecabtagene vicleucel (bb2121/ ide-cel): Bristol-Myers Squibb/Bluebird bio

3. Venetoclax (ABT-199): AbbVie and Roche

4. JNJ-68284528 (LCAR-B38M/JNJ-4528): Janssen Biotech/Nanjing Legend Biotech

5. Melflufen (melphalan flufenamide): Oncopeptides AB

6. Keytruda (Pembrolizumab): Merck Sharp & Dohme Corp.

7. Cetrelimab (JNJ-63723283): Janssen Research & Development

8. REGN5458: Regeneron Pharmaceuticals

9. Felzartamab (MOR202): MorphoSys AG/I-Mab Biopharma

10. Chidamide (Epidaza): Chipscreen Biosciences

11. Iberdomide (CC-220): Bristol-Myers Squibb/Celgene

12. Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy: RAPA Therapeutics

13. Encorafenib in combination with Binimetinib: Pfizer (Array Biopharma)

14. CLR 131 (131-CLR1404): Cellectar Biosciences

15. NY-ESO-1C259T Cells: Adaptimmune Therapeutics /GlaxoSmithKline /Merck Sharp & Dohme Corp

16. BL-8040: BioLineRx

17. GVAX (GM-CSF) Vaccine: Celgene/Aduro Biotech

18. ECT-001: ExCellThera

19. TAK-079: Takeda

20. GBR 1342 (ISB 1342): Glenmark (Ichnos Sciences SA)

21. P-BCMA-101 CAR-T cells: Poseida Therapeutics

22. Opdivo (Nivolumab): Bristol-Myers Squibb

23. AMG 420 (BI 836909): Amgen

24. PBCAR269A: Precision BioSciences

25. JCARH125 (Orvacabtagene autoleucel; Orva-cel): Juno Therapeutics (a Bristol-Myers Squibb company)

26. MP0250: Molecular Partners AG

27. Teclistamab (JNJ-7957; JNJ-64007957): Janssen Pharmaceutical

28. Descartes-11: Cartesian Therapeutics

29. Imfinzi (Durvalumab): AstraZeneca

30. Imbruvica (Ibrutinib): Abbvie (Pharmacyclics) and Johnson & Johnson

Products detail will be provided in the report…

Pipeline Development Activities

Key Points

1. In June 2020, the Company submits NDA application to the US Food and Drug Administration (FDA) for accelerated approval of melflufen (INN melphalan flufenamide) in combination with dexamethasone for the treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody (i.e., triple-class refractory multiple myeloma patients).

2. In May 2020, Bristol-Myers Squibb announced that European Medicines Agency (EMA) has validated its Marketing Authorization Applications (MAA) for idecabtagene vicleucel (ide-cel, bb2121). Validation of each application confirms the respective submission is complete and begins the EMA's centralized review process.

3. In May 2020, Bristol Myers Squibb and bluebird bio announced that the companies received a Refusal to File letter from the US FDA regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020.

4. In February 2020, GlaxoSmithKline announced that the European Medicines Agency (EMA) validated the marketing authorization application (MAA) for Belantamab Mafodotin for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody. Belantamab Mafodotin was accepted for accelerated assessment by the EMA's Committee for Human Medicinal Products (CHMP

5. In December 2019, Janssen announced receipt of a Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for JNJ-4528, which is granted to expedite the development and regulatory review of an investigational medicine that is intended to treat a serious or life-threatening condition.

Multiple Myeloma Drugs Uptake

Among the IMid's agent lenalidomide (Revlimid, Celgene) dominates the Multiple Myeloma market in the 8MM, where it is included in all lines of Multiple Myeloma therapy either as monotherapy or in combination with other drugs. According to a settlement deal between Celgene and Natco Pharma, a limited generic entry will begin in March 2022 for this candidate, after that generic entry will be permitted. In the European Union, the patent is set to expire in 2024, which will lead to the penetration of generics in the European Market. In 2017, Lenalidomide generated a revenue of USD 7,140 million in the 8MM. Despite the loss of patent exclusivity among the major markets and approval of other potential pipeline candidates, lenalidomide as a molecule will likely maintain a strong presence during the forecast period.

Among emerging therapies, Bristol Myers Squibb and Bluebird Bio's anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) expected to generate the maximum revenue owing to promising results, one-time dosing.

Access and Reimbursement Scenario in Multiple Myeloma Therapies

In March 2019, the Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) plus Velcade (bortezomib) and dexamethasone (DVd) for use within the Cancer Drugs Fund (CDF), as an option for treating relapsed multiple myeloma in people who have had one previous treatment. Patients at second line will now have access to a treatment combination, which NICE accepts had a 'clinically important and statistically significant effect on progression-free survival.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Multiple Myeloma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Multiple Myeloma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Multiple Myeloma Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Multiple Myeloma, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the Multiple Myeloma epidemiology and treatment in the 8MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Multiple Myeloma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Multiple Myeloma market; historical and forecasted is included in the report, covering drug outreach in the 8MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Multiple Myeloma market.

Report Highlights:

  • In the coming years, Multiple Myeloma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Multiple Myeloma. Launch of emerging therapies, will significantly impact the Multiple Myeloma market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Multiple Myeloma.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Multiple Myeloma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Multiple Myeloma Pipeline Analysis
  • Multiple Myeloma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Multiple Myeloma Report Key Strengths

  • 11 Years Forecast
  • 8MM Coverage
  • Multiple Myeloma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Multiple Myeloma Report Assessment

  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Multiple Myeloma Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Multiple Myeloma total market Size as well as market size by therapies across the 8MM during the study period (2017-2030)?
  • What are the key findings pertaining to the market across the 8MM and which country will have the largest Multiple Myeloma market size during the study period (2017-2030)?
  • At what CAGR, the Multiple Myeloma market is expected to grow in the 8MM during the study period (2017-2030)?
  • What would be the Multiple Myeloma market outlook across the 8MM during the study period (2017-2030)?
  • What would be the Multiple Myeloma market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • Multiple Myeloma patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Multiple Myeloma market?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Multiple Myeloma?
  • What is the historical Multiple Myeloma patient pool in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan and China?
  • What would be the forecasted patient pool of Multiple Myeloma in 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan and China?
  • What will be the growth opportunities in the 8MM with respect to the patient population pertaining to Multiple Myeloma?
  • Out of all the 8MM countries, which country would have the highest Incident population of Multiple Myeloma during the study period (2017-2030)?
  • At what CAGR the population is expected to grow in the 8MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Multiple Myeloma?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Multiple Myeloma along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Multiple Myeloma in the US, Europe Japan and China?
  • What are the Multiple Myeloma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Multiple Myeloma?
  • How many therapies are developed by each company for the treatment of Multiple Myeloma?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of Multiple Myeloma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Multiple Myeloma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Multiple Myeloma and their status?
  • What are the key designations that have been granted for the emerging therapies for Multiple Myeloma?
  • What are the global historical and forecasted market of Multiple Myeloma?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Multiple Myeloma market.
  • To understand the future market competition in the Multiple Myeloma market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Multiple Myeloma in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) Japan and China.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Multiple Myeloma market.
  • To understand the future market competition in the Multiple Myeloma market.

Table of Contents

1. Key Insights

2. Executive Summary of Multiple Myeloma (MM)

3. KOL Views

4. SWOT Analysis of Multiple Myeloma (MM)

5. Multiple Myeloma: Market Overview at a Glance

6. Disease Background and Overview: Multiple Myeloma (MM)

  • 6.1. Introduction
  • 6.2. Multiple Myeloma features
    • 6.2.1. Low blood counts
    • 6.2.2. Bone and calcium problems
    • 6.2.3. Infections
    • 6.2.4. Kidney problems
  • 6.3. Causes of Multiple Myeloma
  • 6.4. Risk factors of Multiple Myeloma
  • 6.5. Signs and Symptoms
    • 6.5.1. Bone Problems
    • 6.5.2. Low blood counts
    • 6.5.3. High blood levels of calcium
    • 6.5.4. Nervous system symptoms
    • 6.5.5. Kidney Problems
    • 6.5.6. Infections
  • 6.6. Pathogenesis of Multiple Myeloma
    • 6.6.1. Molecular mechanisms underlying the progression of multiple myeloma
    • 6.6.2. Molecular pathogenesis of multiple myeloma and its premalignant precursor
  • 6.7. Pathophysiology of Multiple Myeloma
  • 6.8. Patient-related risk factors
  • 6.9. Biomarkers for Multiple Myeloma
    • 6.9.1. Serum M-protein and light chains as biomarkers
    • 6.9.2. Potential proteomic biomarkers
    • 6.9.3. Cytogenetic biomarkers in multiple myeloma

7. Diagnosis of Multiple Myeloma

  • 7.1. Lab tests
  • 7.2. Biopsies
  • 7.3. Imaging tests
  • 7.4. Stages of Multiple Myeloma

8. Epidemiology and Patient Population

  • 8.1. Epidemiology Key Findings
  • 8.2. Assumptions and Rationale: 8MM
  • 8.3. Epidemiology Scenario: 8MM
    • 8.3.1. Total Incident Cases of Multiple Myeloma in the 8MM
    • 8.3.2. Total Symptomatic Cases of Multiple Myeloma in the 8MM
    • 8.3.3. Gender-specific cases of Multiple Myeloma in the 8MM
    • 8.3.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM
    • 8.3.5. Cases of Multiple Myeloma by Treatment Line in the 8MM

9. The United States Epidemiology

  • 9.1. Total Incident Cases of Multiple Myeloma in the United States
  • 9.2. Total Symptomatic Cases of Multiple Myeloma in the United States
  • 9.3. Gender-specific cases of Multiple Myeloma in the United States
  • 9.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the United States
  • 9.5. Cases of Multiple Myeloma by Treatment Line in the United States

10. EU-5 Epidemiology

  • 10.1. Germany
    • 10.1.1. Total Incident Cases of Multiple Myeloma in Germany
    • 10.1.2. Total Symptomatic Cases of Multiple Myeloma in Germany
    • 10.1.3. Gender-specific cases of Multiple Myeloma in Germany
    • 10.1.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Germany
    • 10.1.5. Cases of Multiple Myeloma by Treatment Line in Germany
  • 10.2. France
    • 10.2.1. Total Incident Cases of Multiple Myeloma in France
    • 10.2.2. Total Symptomatic Cases of Multiple Myeloma in France
    • 10.2.3. Gender-specific cases of Multiple Myeloma in France
    • 10.2.4. Diagnosed cases of Multiple Myeloma by Age Distribution in France
    • 10.2.5. Cases of Multiple Myeloma by Treatment Line in France
  • 10.3. Italy
    • 10.3.1. Total Incident Cases of Multiple Myeloma in Italy
    • 10.3.2. Total Symptomatic Cases of Multiple Myeloma in Italy
    • 10.3.3. Gender-specific cases of Multiple Myeloma in Italy
    • 10.3.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Italy
    • 10.3.5. Cases of Multiple Myeloma by Treatment Line in Italy
  • 10.4. Spain
    • 10.4.1. Total Incident Cases of Multiple Myeloma in Spain
    • 10.4.2. Total Symptomatic Cases of Multiple Myeloma in Spain
    • 10.4.3. Gender-specific cases of Multiple Myeloma in Spain
    • 10.4.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Spain
    • 10.4.5. Cases of Multiple Myeloma by Treatment Line in Spain
  • 10.5. The United Kingdom
    • 10.5.1. Total Incident Cases of Multiple Myeloma in the United Kingdom
    • 10.5.2. Total Symptomatic Cases of Multiple Myeloma in the United Kingdom
    • 10.5.3. Gender-specific cases of Multiple Myeloma in the United Kingdom
    • 10.5.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom
    • 10.5.5. Cases of Multiple Myeloma by Treatment Line in the United Kingdom

11. Japan Epidemiology

  • 11.1. Japan
    • 11.1.1. Total Incident Cases of Multiple Myeloma in Japan
    • 11.1.2. Total Symptomatic Cases of Multiple Myeloma in Japan
    • 11.1.3. Gender-specific cases of Multiple Myeloma in Japan
    • 11.1.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Japan
    • 11.1.5. Cases of Multiple Myeloma by Treatment Line in Japan

12. China Epidemiology

  • 12.1. China
    • 12.1.1. Total Incident Cases of Multiple Myeloma in China
    • 12.1.2. Total Symptomatic Cases of Multiple Myeloma in China
    • 12.1.3. Gender-specific cases of Multiple Myeloma in China
    • 12.1.4. Diagnosed cases of Multiple Myeloma by Age Distribution in China
    • 12.1.5. Cases of Multiple Myeloma by Treatment Line in China

13. Treatment

  • 13.1. Drug therapy for Multiple Myeloma
    • 13.1.1. Chemotherapy
    • 13.1.2. Corticosteroids (steroids)
    • 13.1.3. Immunomodulating agents
    • 13.1.4. Proteasome inhibitors
    • 13.1.5. Histone deacetylase (HDAC) inhibitors
    • 13.1.6. Monoclonal antibodies
    • 13.1.7. Nuclear export inhibitor
    • 13.1.8. Using the drugs together or in combination to treat multiple myeloma
    • 13.1.9. Bisphosphonates for bone disease
  • 13.2. Radiation Therapy for Multiple Myeloma
  • 13.3. Surgery for Multiple Myeloma
  • 13.4. Stem Cell Transplant for Multiple Myeloma
    • 13.4.1. Autologous transplants
    • 13.4.2. Allogeneic transplants
  • 13.5. Supportive Treatments for Patients With Multiple Myeloma
    • 13.5.1. Intravenous immunoglobulin (IVIG)
    • 13.5.2. Treatment for low blood cell counts
    • 13.5.3. Plasmapheresis
  • 13.6. Treatment Options for Multiple Myeloma by Stage
    • 13.6.1. Solitary plasmacytomas
    • 13.6.2. Smoldering multiple myeloma
    • 13.6.3. Active (symptomatic) myeloma
  • 13.7. Factors influencing the choice of therapy at relapse
  • 13.8. Treatment Guidelines for Multiple Myeloma

14. Unmet Needs

15. Patient Journey of Multiple Myeloma

16. Key Endpoints of MM Clinical Trials

17. Marketed Therapies

  • 17.1. Key Cross
  • 17.2. Sarclisa (Isatuximab): Sanofi
    • 17.2.1. Product Description
    • 17.2.2. Regulatory Milestones
    • 17.2.3. Other Developmental Activities
    • 17.2.4. Pivotal Clinical Trial
    • 17.2.5. Ongoing Clinical Pipeline Activity
  • 17.3. Xpovio (Selinexor): Karyopharm
    • 17.3.1. Product Description
    • 17.3.2. Regulatory Milestones
    • 17.3.3. Other Developmental Activities
    • 17.3.4. Pivotal Clinical Trial
    • 17.3.5. Ongoing Clinical Pipeline Activity
  • 17.4. Darzalex (Daratumumab): Janssen Biotech
    • 17.4.1. Product Description
    • 17.4.2. Regulatory Milestones
    • 17.4.3. Other Developmental Activities
    • 17.4.4. Pivotal Clinical Trial
    • 17.4.5. Ongoing Pipeline Activity
  • 17.5. Empliciti (Elotuzumab): Bristol Myers Squibb/AbbVie
    • 17.5.1. Product Description
    • 17.5.2. Regulatory Milestones
    • 17.5.3. Other Developmental Activities
    • 17.5.4. Pivotal Clinical Trials
    • 17.5.5. Ongoing Clinical Pipeline Activity
  • 17.6. Velcade (Bortezomib): Takeda Pharmaceutical/Janssen Pharmaceutical
    • 17.6.1. Product Description
    • 17.6.2. Regulatory Milestones
    • 17.6.3. Other Developmental Activities
    • 17.6.4. Pivotal Clinical Trial
  • 17.7. Pomalyst/Imnovid: Bristol-Myers Squibb Company (Celgene)
    • 17.7.1. Product Description
    • 17.7.2. Regulatory Milestones
    • 17.7.3. Other Developmental Activities
    • 17.7.4. Pivotal Clinical Trials
    • 17.7.5. Ongoing Current Pipeline Activity
  • 17.8. Revlimid (Lenalidomide): Celgene
    • 17.8.1. Product Description
    • 17.8.2. Regulatory Milestones
    • 17.8.3. Other Developmental Activities
    • 17.8.4. Pivotal Clinical Trials
  • 17.9. Farydak (Panobinostat): Secura Bio
    • 17.9.1. Product Description
    • 17.9.2. Regulatory Milestones
    • 17.9.3. Other Developmental Activities
    • 17.9.4. Pivotal Clinical Trials
    • 17.9.5. Ongoing Current Pipeline Activity
  • 17.10. Kyprolis (Carfilzomib): Amgen (Onyx therapeutics)
    • 17.10.1. Product Description
    • 17.10.2. Regulatory Milestones
    • 17.10.3. Other Developmental Activities
    • 17.10.4. Pivotal Clinical Trials
    • 17.10.5. Ongoing Current Pipeline Activity
  • 17.11. Ninlaro (Ixazomib): Takeda Pharmaceutical (Millennium Pharmaceuticals)
    • 17.11.1. Product Description
    • 17.11.2. Regulatory Milestones
    • 17.11.3. Other Developmental Activities
    • 17.11.4. Pivotal Clinical Trials
    • 17.11.5. Ongoing Current Pipeline Activity

18. Emerging Therapies

  • 18.1. Key Cross
  • 18.2. Belantamab Mafodotin (GSK2857916): GlaxoSmithKline
    • 18.2.1. Product Description
    • 18.2.2. Regulatory milestones
    • 18.2.3. Other Developmental Activities
    • 18.2.4. Clinical Development
    • 18.2.5. Safety and Efficacy
  • 18.3. Idecabtagene vicleucel (bb2121/ ide-cel): Bristol-Myers Squibb/Bluebird bio
    • 18.3.1. Product Description
    • 18.3.2. Other Developmental Activities
    • 18.3.3. Clinical Development
    • 18.3.4. Safety and Efficacy
  • 18.4. Venetoclax (ABT-199): AbbVie and Roche
    • 18.4.1. Product Description
    • 18.4.2. Other Developmental Activities
    • 18.4.3. Clinical Development
    • 18.4.4. Safety and Efficacy
  • 18.5. JNJ-68284528 (LCAR-B38M/JNJ-4528): Janssen Biotech/Nanjing Legend Biotech
    • 18.5.1. Product Description
    • 18.5.2. Other Developmental Activities
    • 18.5.3. Clinical Development
    • 18.5.4. Safety and Efficacy
  • 18.6. Melflufen (melphalan flufenamide): Oncopeptides AB
    • 18.6.1. Product Description
    • 18.6.2. Regulatory milestones
    • 18.6.3. Other Developmental Activities
    • 18.6.4. Clinical Development
    • 18.6.5. Safety and Efficacy
  • 18.7. Keytruda (Pembrolizumab): Merck Sharp & Dohme Corp.
    • 18.7.1. Product Description
    • 18.7.2. Other Developmental Activities
    • 18.7.3. Clinical Development
    • 18.7.4. Safety and Efficacy
  • 18.8. Cetrelimab (JNJ-63723283): Janssen Research & Development
    • 18.8.1. Product Description
    • 18.8.2. Clinical Development
  • 18.9. REGN5458: Regeneron Pharmaceuticals
    • 18.9.1. Product Description
    • 18.9.2. Other Developmental Activities
    • 18.9.3. Clinical Development
    • 18.9.4. Safety and Efficacy
  • 18.10. Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
    • 18.10.1. Product Description
    • 18.10.2. Other Developmental Activities
    • 18.10.3. Clinical Development
    • 18.10.4. Safety and Efficacy
  • 18.11. Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy: RAPA Therapeutics
    • 18.11.1. Product Description
    • 18.11.2. Clinical Development
  • 18.12. Encorafenib in combination with Binimetinib: Pfizer (Array Biopharma)
    • 18.12.1. Product Description
    • 18.12.2. Other developmental activities
    • 18.12.3. Clinical development
  • 18.13. CLR 131 (131-CLR1404): Cellectar Biosciences
    • 18.13.1. Product description
    • 18.13.2. Other developmental activities
    • 18.13.3. Clinical development
    • 18.13.4. Safety and Efficacy
  • 18.14. NY-ESO-1C259T Cells: Adaptimmune Therapeutics /GlaxoSmithKline /Merck Sharp & Dohme Corp
    • 18.14.1. Product Description
    • 18.14.2. Other developmental activities
    • 18.14.3. Clinical development
    • 18.14.4. Safety and Efficacy
  • 18.15. BL-8040: BioLineRx
    • 18.15.1. Product description
    • 18.15.2. Other developmental activities
    • 18.15.3. Clinical development
    • 18.15.4. Safety and Efficacy
  • 18.16. GVAX (GM-CSF) Vaccine: Celgene/Aduro Biotech
    • 18.16.1. Product description
    • 18.16.2. Other developmental activities
    • 18.16.3. Clinical development
    • 18.16.4. Safety and Efficacy
  • 18.17. ECT-001: ExCellThera
    • 18.17.1. Product Description
    • 18.17.2. Other Developmental Activities
    • 18.17.3. Clinical development
  • 18.18. TAK-079: Takeda
    • 18.18.1. Product description
    • 18.18.2. Other Developmental Activities
    • 18.18.3. Clinical Development
    • 18.18.4. Safety and Efficacy
  • 18.19. GBR 1342 (ISB 1342): Glenmark (Ichnos Sciences SA)
    • 18.19.1. Product Description
    • 18.19.2. Other Developmental Activities
    • 18.19.3. Clinical Development
  • 18.20. P-BCMA-101 CAR-T cells: Poseida Therapeutics
    • 18.20.1. Product Description
    • 18.20.2. Other Developmental Activities
    • 18.20.3. Clinical Development
    • 18.20.4. Safety and Efficacy
  • 18.21. Opdivo (Nivolumab): Bristol-Myers Squibb
    • 18.21.1. Product Description
    • 18.21.2. Other Developmental Activities
    • 18.21.3. Clinical Development
    • 18.21.4. Safety and Efficacy
  • 18.22. AMG 420 (BI 836909): Amgen
    • 18.22.1. Product Description
    • 18.22.2. Other Developmental Activities
    • 18.22.3. Clinical Development
    • 18.22.4. Safety and Efficacy
  • 18.23. PBCAR269A: Precision BioSciences
    • 18.23.1. Product Description
    • 18.23.2. Other Developmental Activities
    • 18.23.3. Clinical Development
  • 18.24. JCARH125 (Orvacabtagene autoleucel; Orva-cel): Juno Therapeutics (a Bristol-Myers Squibb company)
    • 18.24.1. Product Description
    • 18.24.2. Other Developmental Activities
    • 18.24.3. Clinical Development
    • 18.24.4. Safety and Efficacy
  • 18.25. MP0250: Molecular Partners AG
    • 18.25.1. Product Description
    • 18.25.2. Other Developmental Activities
    • 18.25.3. Clinical Development
    • 18.25.4. Safety and Efficacy
  • 18.26. Teclistamab (JNJ-7957; JNJ-64007957): Janssen Pharmaceutical
    • 18.26.1. Product Description
    • 18.26.2. Other Developmental Activities
    • 18.26.3. Clinical Development
    • 18.26.4. Safety and Efficacy
  • 18.27. Descartes-11: Cartesian Therapeutics
    • 18.27.1. Product Description
    • 18.27.2. Clinical Development
  • 18.28. Imfinzi (Durvalumab): AstraZeneca
    • 18.28.1. Product Description
    • 18.28.2. Other Developmental Activities
    • 18.28.3. Clinical Development
    • 18.28.4. Safety and Efficacy
  • 18.29. Imbruvica (Ibrutinib): Abbvie (Pharmacyclics) and Johnson & Johnson
    • 18.29.1. Product Description
    • 18.29.2. Other Developmental Activities
    • 18.29.3. Clinical Development
    • 18.29.4. Safety and Efficacy
  • 18.30. Felzartamab (MOR202): MorphoSys AG/I-Mab Biopharma
    • 18.30.1. Product Description
    • 18.30.2. Other Developmental Activities
    • 18.30.3. Clinical Development
    • 18.30.4. Safety and Efficacy
  • 18.31. Chidamide (Epidaza): Chipscreen Biosciences
    • 18.31.1. Product Description
    • 18.31.2. Other Developmental Activities
    • 18.31.3. Clinical Development
    • 18.31.4. Safety and Efficacy

19. Multiple Myeloma (MM): Eight Major Market Analysis

  • 19.1. Key Findings
  • 19.2. Market Outlook: 8MM
  • 19.3. China Market Outlook

20. 8MM Market Size

  • 20.1. Total Market size of Multiple Myeloma in the 8MM
  • 20.2. Total Market size of Multiple Myeloma by Therapies in the 8MM

21. The United States Market Size

  • 21.1. Total Market size of Multiple Myeloma in the United States

22. EU-5 Market Size

  • 22.1. Germany
    • 22.1.1. Total Market size of Multiple Myeloma in Germany
  • 22.2. France
    • 22.2.1. Total Market size of Multiple Myeloma in France
  • 22.3. Italy
    • 22.3.1. Total Market size of Multiple Myeloma in Italy
  • 22.4. Spain
    • 22.4.1. Total Market size of Multiple Myeloma in Spain
  • 22.5. The United Kingdom
    • 22.5.1. Total Market size of Multiple Myeloma in the United Kingdom

23. Japan Market Size

  • 23.1. Total Market size of Multiple Myeloma in Japan

24. China Market Size

  • 24.1. The total Market size of Multiple Myeloma in China

25. Market Access and Reimbursement of Multiple Myeloma (MM) Therapies

  • 25.1. European Market Access Challenges for Relapsed Refractory Multiple Myeloma Triplet Therapies

26. Market Drivers

27. Market Barriers

28. Appendix

  • 28.1. Bibliography
  • 28.2. Report Methodology

29. DelveInsight Capabilities

30. Disclaimer

31. About DelveInsight

List of Tables

  • Table 1 Summary of MM Market, Epidemiology, and Key Events (2017-2030)
  • Table 2 Cytogenetic Abnormalities on Clinical Course and Prognosis in Multiple Myeloma
  • Table 3 The Revised International Staging System
  • Table 4 International Myeloma Working Group (IMWG) Diagnostic Criteria for Multiple Myeloma and Related Plasma Cell Disorders
  • Table 5 Recommendations for the use of ¹?F-FDG PET/CT in patients with multiple myeloma and other plasma cell disorders
  • Table 6 Total Incident Cases of Multiple Myeloma in the 8MM (2017-2030)
  • Table 7 Total Symptomatic Cases of Multiple Myeloma in the 8MM (2017-2030)
  • Table 8 Gender-specific cases of Multiple Myeloma in the 8MM (2017-2030)
  • Table 9 Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM (2017-2030)
  • Table 10 Cases of Multiple Myeloma by Treatment Line in the 8MM (2017-2030)
  • Table 11 Total Incident Cases of Multiple Myeloma in the United States (2017-2030)
  • Table 12 Total Symptomatic Cases of Multiple Myeloma in the United States (2017-2030)
  • Table 13 Gender-specific cases of Multiple Myeloma in the United States (2017-2030)
  • Table 14 Diagnosed cases of Multiple Myeloma by Age Distribution in the United States (2017-2030)
  • Table 15 Cases of Multiple Myeloma by Treatment Line in the United States (2017-2030)
  • Table 16 Total Incident Cases of Multiple Myeloma in Germany (2017-2030)
  • Table 17 Total Symptomatic Cases of Multiple Myeloma in Germany (2017-2030)
  • Table 18 Gender-specific cases of Multiple Myeloma in Germany (2017-2030)
  • Table 19 Diagnosed cases of Multiple Myeloma by Age Distribution in Germany (2017-2030)
  • Table 20 Cases of Multiple Myeloma by Treatment Line in Germany (2017-2030)
  • Table 21 Total Incident Cases of Multiple Myeloma in France (2017-2030)
  • Table 22 Total Symptomatic Cases of Multiple Myeloma in France (2017-2030)
  • Table 23 Gender-specific cases of Multiple Myeloma in France (2017-2030)
  • Table 24 Diagnosed cases of Multiple Myeloma by Age Distribution in France (2017-2030)
  • Table 25 Cases of Multiple Myeloma by Treatment Line in France (2017-2030)
  • Table 26 Total Incident Cases of Multiple Myeloma in Italy (2017-2030)
  • Table 27 Total Symptomatic Cases of Multiple Myeloma in Italy (2017-2030)
  • Table 28 Gender-specific cases of Multiple Myeloma in Italy (2017-2030)
  • Table 29 Diagnosed cases of Multiple Myeloma by Age Distribution in Italy (2017-2030)
  • Table 30 Cases of Multiple Myeloma by Treatment Line in Italy (2017-2030)
  • Table 31 Total Incident Cases of Multiple Myeloma in Spain (2017-2030)
  • Table 32 Total Symptomatic Cases of Multiple Myeloma in Spain (2017-2030)
  • Table 33 Gender-specific cases of Multiple Myeloma in Spain (2017-2030)
  • Table 34 Diagnosed cases of Multiple Myeloma by Age Distribution in Spain (2017-2030)
  • Table 35 Cases of Multiple Myeloma by Treatment Line in Spain (2017-2030)
  • Table 36 Total Incident Cases of Multiple Myeloma in the United Kingdom (2017-2030)
  • Table 37 Total Symptomatic Cases of Multiple Myeloma in the United Kingdom (2017-2030)
  • Table 38 Gender-specific cases of Multiple Myeloma in the United Kingdom (2017-2030)
  • Table 39 Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom (2017-2030)
  • Table 40 Cases of Multiple Myeloma by Treatment Line in the United Kingdom (2017-2030)
  • Table 41 Total Incident Cases of Multiple Myeloma in Japan (2017-2030)
  • Table 42 Total Symptomatic Cases of Multiple Myeloma in Japan (2017-2030)
  • Table 43 Gender-specific cases of Multiple Myeloma in Japan (2017-2030)
  • Table 44 Diagnosed cases of Multiple Myeloma by Age Distribution in Japan (2017-2030)
  • Table 45 Cases of Multiple Myeloma by Treatment Line in Japan (2017-2030)
  • Table 46 Total Incident Cases of Multiple Myeloma in China (2017-2030)
  • Table 47 Total Symptomatic Cases of Multiple Myeloma in China (2017-2030)
  • Table 48 Gender-specific cases of Multiple Myeloma in China (2017-2030)
  • Table 49 Diagnosed cases of Multiple Myeloma by Age Distribution in China (2017-2030)
  • Table 50 Cases of Multiple Myeloma by Treatment Line in China (2017-2030)
  • Table 51 Guidelines for the first-line treatment of multiple myeloma
  • Table 52 Recommendations for the management of relapsed or refractory multiple myeloma
  • Table 53 Marketed Drugs Key Cross
  • Table 54 Sarclisa, Clinical Trial Description, 2020
  • Table 55 Selinexor, Clinical Trial Description, 2020
  • Table 56 Daratumumab, Clinical Trial Description, 2020
  • Table 57 Elotuzumab, Clinical Trial Description, 2020
  • Table 58 Pomalyst/Imnovid, Clinical Trial Description, 2020
  • Table 59 Panobinostat (Farydak), Clinical Trial Description, 2020
  • Table 60 Carfilzomib (Kyprolis), Clinical Trial Description, 2020
  • Table 61 Ninlaro (Ixazomib), Clinical Trial Description, 2020
  • Table 62 Emerging Key Cross
  • Table 63 Belantamab mafodotin, Clinical Trial Description, 2020
  • Table 64 Idecabtagene vicleucel (bb2121/ ide-cel), Clinical Trial Description, 2020
  • Table 65 Venetoclax, Clinical Trial Description, 2020
  • Table 66 JNJ-68284528, Clinical Trial Description, 2020
  • Table 67 Melflufen, Clinical Trial Description, 2020
  • Table 68 Keytruda(Pembrolizumab), Clinical Trial Description, 2020
  • Table 69 Cetrelimab (JNJ-63723283), Clinical Trial Description, 2020
  • Table 70 REGN5458, Clinical Trial Description, 2020
  • Table 71 Iberdomide, Clinical Trial Description, 2020
  • Table 72 Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy, Clinical Trial Description, 2020
  • Table 73 Encorafenib (LGX818) plus Binimetinib (MEK162), Clinical Trial Description, 2020
  • Table 74 NY-ESO-1C259T Cells-, Clinical Trial Description, 2020
  • Table 75 BL-8040, Clinical Trial Description, 2020
  • Table 76 GVAX (GM-CSF), Clinical Trial Description, 2020
  • Table 77 ECT-001, Clinical Trial Description, 2020
  • Table 78 TAK-079, Clinical Trial Description, 2020
  • Table 79 GBR-1342, Clinical Trial Description, 2020
  • Table 80 P-BCMA-101, Clinical Trial Description, 2020
  • Table 81 Opdivo (nivolumab), Clinical Trial Description, 2020
  • Table 82 AMG 420, Clinical Trial Description, 2020
  • Table 83 PBCAR269A, Clinical Trial Description, 2020
  • Table 84 JCARH125, Clinical Trial Description, 2020
  • Table 85 MP0250, Clinical Trial Description, 2020
  • Table 86 JNJ-64007957, Clinical Trial Description, 2020
  • Table 87 Descartes-11, Clinical Trial Description, 2020
  • Table 88 Imfinzi, Clinical Trial Description, 2020
  • Table 89 Ibrutinib, Clinical Trial Description, 2020
  • Table 90 Felzartamab (MOR202, TJ202)
  • Table 91 Chidamide, Clinical Trial Description, 2020
  • Table 92 8MM Market Size of Multiple Myeloma, in USD Million (2017-2030)
  • Table 93 Market Size of Multiple Myeloma in the 8MM by Therapy, in USD Millions (2017-2030)
  • Table 94 Total Market size of Multiple Myeloma in the United States, in USD Million (2017-2030)
  • Table 95 Market Size of Multiple Myeloma in the United States by Therapy, in USD Millions (2017-2030)
  • Table 96 Total Market size of Multiple Myeloma in Germany, in USD Million (2017-2030)
  • Table 97 Market Size of Multiple Myeloma in Germany by Therapy, in USD Millions (2017-2030)
  • Table 98 Total Market size of Multiple Myeloma in France, in USD Million (2017-2030)
  • Table 99 Market Size of Multiple Myeloma in France by Therapy, in USD Millions (2017-2030)
  • Table 100 Total Market size of Multiple Myeloma in Italy, in USD Million (2017-2030)
  • Table 101 Market Size of Multiple Myeloma in Italy by Therapy, in USD Millions (2017-2030)
  • Table 102 Total Market size of Multiple Myeloma in Spain, in USD Million (2017-2030)
  • Table 103 Market Size of Multiple Myeloma in Spain by Therapy, in USD Millions (2017-2030)
  • Table 104 Total Market size of Multiple Myeloma in the United Kingdom, in USD Million (2017-2030)
  • Table 105 Market Size of Multiple Myeloma in the United Kingdom by Therapy, in USD Millions (2017-2030)
  • Table 106 Total Market size of Multiple Myeloma in Japan, in USD Million (2017-2030)
  • Table 107 Market Size of Multiple Myeloma in Japan by Therapy, in USD Millions (2017-2030)
  • Table 108 Total Market size of Multiple Myeloma in China, in USD Million (2017-2030)
  • Table 109 Market Size of Multiple Myeloma in China by Therapy, in USD Millions (2017-2030)
  • Table 110 Product Combinations in Scope
  • Table 111 Restricted HTA Outcomes
  • Table 112 HTA outcome of the Second Assessment of Carfilzomib (CLd)
  • Table 113 Key HTA decisions for MM Therapies

List of Figures

  • Figure 1 Multiple Myeloma (MM) SWOT Analysis
  • Figure 2 Interactions of MM tumor cells with the BM microenvironment. Five kinds of cells in the BM microenvironment are depicted, as well as a few of the complex interactions among these cells and MM cells.
  • Figure 3 Interaction of multiple myeloma cells in their bone marrow milieu
  • Figure 4 Technological advances in detecting biomarkers in multiple myeloma.
  • Figure 5 The National Comprehensive Cancer Network (NCCN) recommendations for initial diagnostic workup of patients with suspected MM
  • Figure 6 Global Heat Map of Multiple Myeloma
  • Figure 7 Total Incident Cases of Multiple Myeloma in the 8MM (2017-2030)
  • Figure 8 Symptomatic Cases of Multiple Myeloma in the 8MM (2017-2030)
  • Figure 9 Gender-specific cases of Multiple Myeloma in the 8MM (2017-2030)
  • Figure 10 Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM (2017-2030)
  • Figure 11 Cases of Multiple Myeloma by Treatment Line in the 8MM (2017-2030)
  • Figure 12 Total Incident Cases of Multiple Myeloma in the United States (2017-2030)
  • Figure 13 Symptomatic Cases of Multiple Myeloma in the United States (2017-2030)
  • Figure 14 Gender-specific cases of Multiple Myeloma in the United States (2017-2030)
  • Figure 15 Diagnosed cases of Multiple Myeloma by Age Distribution in the United States (2017-2030)
  • Figure 16 Cases of Multiple Myeloma by Treatment Line in the United States (2017-2030)
  • Figure 17 Total Incident Cases of Multiple Myeloma in Germany (2017-2030)
  • Figure 18 Symptomatic Cases of Multiple Myeloma in Germany (2017-2030)
  • Figure 19 Gender-specific cases of Multiple Myeloma in Germany (2017-2030)
  • Figure 20 Diagnosed cases of Multiple Myeloma by Age Distribution in Germany (2017-2030)
  • Figure 21 Cases of Multiple Myeloma by Treatment Line in Germany (2017-2030)
  • Figure 22 Total Incident Cases of Multiple Myeloma in France (2017-2030)
  • Figure 23 Symptomatic Cases of Multiple Myeloma in France (2017-2030)
  • Figure 24 Gender-specific cases of Multiple Myeloma in France (2017-2030)
  • Figure 25 Diagnosed cases of Multiple Myeloma by Age Distribution in France (2017-2030)
  • Figure 26 Cases of Multiple Myeloma by Treatment Line in France (2017-2030)
  • Figure 27 Total Incident Cases of Multiple Myeloma in Italy (2017-2030)
  • Figure 28 Symptomatic Cases of Multiple Myeloma in Italy (2017-2030)
  • Figure 29 Gender-specific cases of Multiple Myeloma in Italy (2017-2030)
  • Figure 30 Diagnosed cases of Multiple Myeloma by Age Distribution in Italy (2017-2030)
  • Figure 31 Cases of Multiple Myeloma by Treatment Line in Italy (2017-2030)
  • Figure 32 Total Incident Cases of Multiple Myeloma in Spain (2017-2030)
  • Figure 33 Symptomatic Cases of Multiple Myeloma in Spain (2017-2030)
  • Figure 34 Gender-specific cases of Multiple Myeloma in Spain (2017-2030)
  • Figure 35 Diagnosed cases of Multiple Myeloma by Age Distribution in Spain (2017-2030)
  • Figure 36 Cases of Multiple Myeloma by Treatment Line in Spain (2017-2030)
  • Figure 37 Total Incident Cases of Multiple Myeloma in the United Kingdom (2017-2030)
  • Figure 38 Symptomatic Cases of Multiple Myeloma in the United Kingdom (2017-2030)
  • Figure 39 Gender-specific cases of Multiple Myeloma in the United Kingdom (2017-2030)
  • Figure 40 Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom (2017-2030)
  • Figure 41 Cases of Multiple Myeloma by Treatment Line in the United Kingdom (2017-2030)
  • Figure 42 Total Incident Cases of Multiple Myeloma in Japan (2017-2030)
  • Figure 43 Symptomatic Cases of Multiple Myeloma in Japan (2017-2030)
  • Figure 44 Gender-specific cases of Multiple Myeloma in Japan (2017-2030)
  • Figure 45 Diagnosed cases of Multiple Myeloma by Age Distribution in Japan (2017-2030)
  • Figure 46 Cases of Multiple Myeloma by Treatment Line in Japan (2017-2030)
  • Figure 47 Total Incident Cases of Multiple Myeloma in China (2017-2030)
  • Figure 48 Symptomatic Cases of Multiple Myeloma in China (2017-2030)
  • Figure 49 Gender-specific cases of Multiple Myeloma in China (2017-2030)
  • Figure 50 Diagnosed cases of Multiple Myeloma by Age Distribution in China (2017-2030)
  • Figure 51 Cases of Multiple Myeloma by Treatment Line in China (2017-2030)
  • Figure 52 Factors influencing the choice of therapy at relapse
  • Figure 53 Treatment algorithm for Relapsing Refractory Multiple Myeloma
  • Figure 54 Algorithm on treatment of patients with multiple myeloma
  • Figure 55 The NCCN Recommendations for follow-up of patients with MM after primary treatment
  • Figure 56 The NCCN Recommendations for Primary Myeloma Therapy
  • Figure 57 The NCCN Recommendations for Myeloma Therapy
  • Figure 58 The NCCN Recommendations for Lenalidomide Maintenance
  • Figure 59 The NCCN Recommendations for Management of Renal Disease in Patients With MM
  • Figure 60 Unmet Needs of Multiple Myeloma
  • Figure 61 Mechanism of Action of MesoPher
  • Figure 62 Total Market Size of Multiple Myeloma in the 8MM, in USD Millions (2017-2030)
  • Figure 63 Market Size of Multiple Myeloma in the 8MM by Therapies, in USD Millions (2017-2030)
  • Figure 64 Market Size of Multiple Myeloma in the United States by Therapy, in USD Millions (2017-2030)
  • Figure 65 Market Size of Multiple Myeloma in Germany by Therapy, in USD Millions (2017-2030)
  • Figure 66 Market Size of Multiple Myeloma in France by Therapy, in USD Millions (2017-2030)
  • Figure 67 Market Size of Multiple Myeloma in Italy by Therapy, in USD Millions (2017-2030)
  • Figure 68 Market Size of Multiple Myeloma in Spain by Therapy, in USD Millions (2017-2030)
  • Figure 69 Market Size of Multiple Myeloma in the United Kingdom by Therapy, in USD Millions (2017-2030)
  • Figure 70 Market Size of Multiple Myeloma in Japan by Therapy, in USD Millions (2017-2030)
  • Figure 71 Market Size of Multiple Myeloma in China by Therapy, in USD Millions (2017-2030)
  • Figure 72 Comparison of HTA recommendations across triplet therapies
  • Figure 73 Time from EMA MA to First Accepted or Restricted HTA Outcome
  • Figure 74 Comparative availability over time of ixazomib for new patients with relapsed or refractory multiple myeloma between France and England and main milestones of the appraisal.
  • Figure 75 Market Drivers
  • Figure 76 Market Barriers